Andres Poveda, MD, on the Phase III SOLO2/ENGOT-ov21 Final OS Data in Ovarian Cancer

Final overall survival (OS) results from the phase III SOLO2/ENGOT-ov21 trial demonstrated that maintenance olaparib (Lynparza) provided an unprecedented improvement in median OS versus placebo in patients with platinum-sensitive, relapsed ovarian cancer with a BRCA mutation.

Presented at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program, this is the first study with olaparib tablets, and the first since Study 19, to provide long-term follow-up and final OS data in this patient population. 

In an interview with CancerNetwork^®, Andres Poveda, MD, of the Fundación Instituto Valenciano de Oncologia in Valencia, Spain, discussed the study design and the results presented at the meeting. 

Transcription:

The study design is for patients with high-grade serous ovarian cancer and BRCA mutation. Patients were randomized to olaparib tablets or placebo and continued the study treatment until disease progression. And a key secondary endpoint is overall survival. The study was designed knowing that olaparib is active in BRCA mutated patients, according to the previous information of some different studies. And 3 years ago, the report of the PFS was really brilliant and incredible. The results that we have now are the overall survival results.

The final analysis, median overall survival, improved by close to 15 months with maintenance olaparib over placebo. This is impressive, so this is the first time in the last close to twenty years that we have had benefit in overall survival for patients in relapsed ovarian cancer… And this is the reason why we are so happy according to the results, because our patients will enjoy this benefit in overall survival, which is so difficult to obtain in patients with relapsed ovarian cancer.